Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of CKD-843 A in Male Subjects
NCT05587699Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-843 in androgenetic alopecia (AGA) (5 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Area Under the Curve from time 0 to Day 271. Started Nov 2022; status: completed.
02
Drugs
CKD-843
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05587699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587699.